Delivery Order SPE2DR25D3013-SPE2DR26F6W8D
- Not listed
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The contract has a completion date of February 27, 2024 and a potential value of $4,202.62. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp serves as the prime contractor for this delivery order, which is...
- The Defense Logistics Agency awarded a $8,990.27 delivery order to AmerisourceBergen Drug Corp on January 7, 2026, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens, with a completion date of January 8, 2026. This firm fixed-price contract was competitively awarded with no set-aside designation and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Lantus SoloStar 100 unit/mL 3mL insulin pens. The $2,375.20 contract has an ultimate completion date of April 1, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00, which serves as the primary...
- The Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The $1,002.40 contract is for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 with Amerisourcebergen Drug Corp as the sole prime...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Lantus SoloStar insulin pens. The $6,156.39 order has a completion date of February 27, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00 through December 31, 2025. This IDC serves as the primary contract vehicle for...
- The Defense Logistics Agency (DLA) awarded a $1,839.84 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on December 18, 2025, with an ultimate completion date of December 19, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement needs,...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Lantus SoloStar 100 unit/mL 3mL insulin pens. The $1,511.42 contract has a completion date of March 5, 2024. Amerisourcebergen Drug Corp is the prime contractor and has no major subcontractors listed. This delivery order is being issued under an indefinite delivery contract (IDC) with a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens, valued at $1,312.94. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of December 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement across...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Lantus Solostar 100 unit/ml 3ml insulin pens. The $1,850.53 contract has a performance period through March 12, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,266.96 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This was a competitively awarded, non-set-aside contract with firm fixed pricing, completed on January 9, 2026. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen's parent company Cencora,...
- SPE2DR25D3013Indefinite Delivery Contract
- SPE2DR25D3013-SPE2DR26F6W8DDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp (a subsidiary of Cencora, Inc.) on January 12, 2026, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens with a ceiling value of $1,397.57. This is a firm fixed-price, non-set-aside contract with a completion date of January 13, 2026, and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The prime IDC, valued at up to $999.9 million through December 2026, serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in supplying prescription medications, generic drugs, vaccines, and medical devices across multiple therapeutic domains to military treatment facilities and other government healthcare systems. The company's extensive portfolio of DLA contract awards demonstrates its capability to compete successfully in open competition for federal medical procurement across diverse product categories, including specialty medications for diabetes management, neurological conditions, pain management, and other specialized medical treatments.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 1/11/26 |